April 10, 2018 / 4:58 PM / 11 days ago

BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial

Reuters Staff

1 Min Read

April 10 (Reuters) - Five Prime Therapeutics Inc:

* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN

* SAYS TO CONTINUE TREATING BLADDER CANCER PATIENTS CURRENTLY ON STUDY BUT WILL NOT ENROLL ADDITIONAL PATIENTS IN COHORT-SEC FILING Source text: (bit.ly/2HnAIag) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.